We are studying whether Nucresiran can help reduce serious heart-related events in patients with transthyretin amyloidosis. The trial compares its effects to a placebo to assess overall health improvements.
Health conditions and diseases that the clinical trial is designed to study and treat.
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy) is a rare condition where abnormal protein deposits in the heart muscle lead to heart dysfunction, causing symptoms like shortness of breath, fatigue, and swelling in the legs.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
